Fibroblast Activation Protein alpha (FAP)

Where the papers sit

13 papers from the last 6 months study Fibroblast Activation Protein alpha (FAP) directly · updated from PubMed 12 Oct 2026

• FAP Radiotracers and Theranostics

  FAP targeting is moving from tracer development toward integrated tumor imaging, cellular therapy and radiotherapeutic or drug-conjugate applications. 68Ga-FAPI PET/CT is being tested for tumor detection and preoperative assessment of peritoneal carcinomatosis against surgicopathologic findings. Dimeric, glycosylated and heterodimeric radioligands seek stronger tumor uptake, while UniCAR modules and FAP drug conjugates extend treatment options. Validation spans solid tumors, glioblastoma models and spontaneous canine tumors.

  6 papers · 46.2%

• FAP-Directed Fibrosis Therapies

  In situ CAR macrophages and T cells are being paired with FAP-responsive carriers to remodel fibrotic tissue. mRNA-loaded LNPs and CAR exosomes target activated hepatic stellate cells or intrauterine adhesions, while FAP-responsive particles aim to improve stromal penetration in fibrotic hepatocellular carcinoma. Recurring endpoints include reduced fibrosis, altered immune microenvironments and better drug access. Evidence remains predominantly preclinical, with metabolic dysfunction-associated steatotic liver disease providing mechanistic context.

  5 papers · 38.5%

• CAF Immune Niche Remodeling

  Myofibro-inflammatory CAF programs are being resolved at single-cell and spatial levels, with FOSB and CXCL8 among the recurring inflammatory signals. FAP-targeted LTβR agonism then uses this stromal biology to drive high endothelial venule differentiation and immune-niche formation. The therapeutic goal is to improve immune-cell entry and response to immunotherapy in solid tumors, particularly triple-negative breast cancer. The evidence remains early and mechanistic, with clinical benefit still to be established.

  2 papers · 15.4%